Dicerna Pharmaceuticals, Inc.’s collaboration agreement with Alexion Pharmaceuticals, Inc.

Foley Hoag LLP advised Dicerna Pharmaceuticals, Inc. on the transaction

Dicerna entered into a collaboration with Alexion Pharmaceuticals, Inc. to discover and develop RNA interference therapies for complement-mediated diseases.

Dicerna Pharmaceuticals, Inc. provides biopharmaceutical products. The Company, led by Douglas M Fambrough III, John B Green and James B Weissman, discovers and develops ribonucleic acid for the treatment of liver diseases and cancer. In 2017 the company recorded $2.3 Million revenues.

Foley Hoag advised Dicerna with team of Hemmie Chang (Picture), Karen Tepichin and Mark Potash

 

Involved fees earner: Hemmie Chang – Foley Hoag; Mark Potash – Foley Hoag; Karen Tepichin – Foley Hoag;

Law Firms: Foley Hoag;

Clients: Dicerna Pharmaceuticals, Inc. ;

Author: Ambrogio Visconti